Finding
Structure Therapeutics’ Oral GLP-1 Achieves Comparable Weight Loss to Lilly’s Candidate
Structure Therapeutics, GLP-1, Obesity, Weight Loss, Lilly, Oral Candidate
LGBTQ+ Populations Face Higher Cancer Risk Due to Barriers to Healthcare
LGBTQ+, cancer risk, barriers to healthcare, American Cancer Society, discrimination, minority stress
Eli Lilly Invests $5.3 Billion to Boost Production of Mounjaro and Zepbound
** Eli Lilly, Mounjaro, Zepbound, Manufacturing, Investment, Diabetes, Obesity, Weight Loss, Pharmaceutical Industry
Merck KGaA Evades Legal Action Following DOJ Collaboration on China Export Investigation
Merck KGaA, DOJ, China, export scheme, cooperation, investigation, prosecution avoidance
AltruBio Secures $225 Million for Phase II Trials of Novel Immune Checkpoint Enhancing Antibody
AltruBio, funding, Phase II trials, immune checkpoint enhancing antibody, cancer treatment, immunotherapy, biotechnology, healthcare innovation.
Tremfya Phase III Maintenance Study Results Presented by J&J for Ulcerative Colitis Treatment
J&J, Johnson & Johnson, Tremfya, guselkumab, Phase III trial, maintenance study, ulcerative colitis, inflammatory bowel disease, treatment, efficacy, safety, remission.
AstraZeneca’s COVID-19 Antibody Treatment Shows Promising Results in Immunocompromised Individuals
AstraZeneca, COVID-19, antibody treatment, immunocompromised individuals, enhanced protection, clinical trials, monoclonal antibodies, virus neutralization, immune response.
ICER Raises Concerns Over Uncertainties in Lykos MDMA Clinical Trials Ahead of FDA Advisory Committee Meeting
ICER, Lykos, MDMA, clinical trials, uncertainties, FDA, AdComm, advisory committee meeting
Novo Nordisk’s Wegovy Demonstrates Long-Term Weight Loss Success in New Analysis
Novo Nordisk, Wegovy, weight loss, long-term, four years, analysis, obesity treatment, semaglutide, sustained weight loss, diabetes, cardiovascular disease.
The Closure of Walmart Health Highlights Significant Hurdles for Retail Health Innovators
Walmart Health, retail health, disruptors, challenges, closure, innovation, healthcare, accessibility, competition, patient engagement, healthcare landscape.